News & Media / Newsroom
In alignment with our strategic development plan, we are pleased to announce that the new subsidiary Alfasigma Deutschland GmbH with headquarter in Munich is operative, starting from 1st October 2022.
Virtus Alfasigma Tournament and Race For The Cure. Double events that saw the people of Alfasigma engaged in a weekend dedicated to youth, wellness and prevention.
CARNITENE®[1] (L-carnitine), the blockbuster product of Alfasigma Group, was approved for marketing in China in the early 21stcentury. Since July 1, the right to distribute the product in China has been held by Kyuan Xinhai (Beijing) Medical Products Trade Co., Ltd.
SOFAR is an Italian company specializing in pharmaceutical products, food supplements and medical devices.
Alfasigma consolidates its leadership in the gastrointestinal area and the research focus on the microbiota.
The acquisition is expected to be completed in October 2022.
Ahead of World Digestive Health 2022, Italian pharmaceutical group Alfasigma is proud to announce the launch of its new diagnostic drug Lumeblue™ (per-oral methylene blue). This latest innovation is part of the company’s commitment to raising awareness on colorectal cancer (CRC), still the second leading cause of cancer deaths worldwide, through a healthy lifestyle and regular screenings.
#LeaveYourMark is back. #LeaveYourMark 2022 goes international sharing thoughts and experiences of Alfasigma colleagues from all over the world online.
[email protected]
+39.051.6489.562
+39.051.6489.884
+39.06.9139.4396
You’re entering Alfasigma global website
I agree